AKT1 and neoplasm: Preclinical studies using tumor cell lines have also shown promising results when CDK inhibitors have been used in combination with other targeted therapies, such as histone deacetylase inhibitors (MS-275 and vorinostat)[40,41] and AKT inhibitors[42].